Abstract 584P
Background
PreC study supported ColonAiQ® (a blood-based assay targeting circulating tumor DNA methylation) as a robust noninvasive option for colorectal cancer (CRC) and advanced adenoma (AA) screening to efficiently stratify individuals with a higher risk based on the first year’s real-world data reported in 2022 World Congress on Gastrointestinal Cancer (LBA SO-23). Here, the update CRC screening outcome was reported.
Methods
105,285 participants living in the local community, aging from 40 to 80, were recruited from Jan 2021 to Dec 2022. ColonAiQ® test was used as the primary screening method for all participants and a follow-up colonoscopy was recommended after a positive primary test. Numbers of positive ColonAiQ® test, colonoscopy compliance rate and positive predictive values (PPV) for AA and/or CRC were determined.
Results
Overall, a total of 6,759 participants (6.42%) were tested positive via ColonAiQ® test. In the positive test population, 3,282 (48.56%) participants performed colonoscopy with pathological confirmation. Overall, there were 1,773 (54.02%) participants confirmed with colonoscopy findings, including 63 (1.92%) CRC, 441 (13.44%) AA, 754 (22.97%) non-advanced adenoma, 327 (9.96%) polyps, and 188 (5.73%) non-neoplastic GI disorders. Particularly, early colorectal neoplasm diagnosis rate reached 90.28%. Therefore, The predictive value (PPV) was 1.92% for CRC and 36.41% for adenoma (13.44% for AA).
Conclusions
The 2-year real world study confirms the initial findings that population compliance rate of colonoscopy is obviously higher than the average rate in Cancer Screening Program in Urban China (48.56% VS 17.25%). ColonAiQ® test could help to identify the asymptomatic patients with neoplasm who need endoscopic resection or surgery excision. These results warrant the cost-effectiveness of the two-step screening pattern in community populations from the ongoing PreC study.
Clinical trial identification
NCT05336539.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Singlera Genomics Inc.
Disclosure
Y. Li, Q. Yuan, H. Luo, C. Wang, Y. Li, W. Pan, H. Yang, H. Jia, B. li, Y. Zhang, R. Liu: Financial Interests, Institutional, Full or part-time Employment: Singlera Genomics Inc. All other authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10